Laura Sirott
Obstetrics & Gynecology · Pasadena, CANPI 1659372530
Payments from drug & device makers
Across 111 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$936
- Pfizer$219
- Bayer$160
- Sumitomo Pharma America, Inc.$98
- Myovant Sciences Inc.$96
- Aspira Women's Health Inc$78
- plus $685 from 18 others
What the payments were for
- Food & beverage$2,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $936 |
| Pfizer | 11 | $219 |
| Bayer | 3 | $160 |
| Sumitomo Pharma America, Inc. | 5 | $98 |
| Myovant Sciences Inc. | 6 | $96 |
| Aspira Women's Health Inc | 3 | $78 |
| Mayne Pharma Commercial LLC | 3 | $75 |
| Coopersurgical, Inc. | 4 | $75 |
| Johnson & Johnson | 3 | $63 |
| Meditrina | 1 | $63 |
| Merck | 3 | $61 |
| Astellas Pharma US Inc | 2 | $41 |
| Zyla Life Sciences, Inc. | 2 | $36 |
| Exeltis, USA Inc. | 2 | $35 |
| Organon | 2 | $35 |
| Therapeuticsmd, Inc. | 2 | $33 |
| Mylan Pharmaceuticals Inc. | 1 | $28 |
| Urovant Sciences Inc | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Evofem Biosciences, Inc. | 2 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Ascend Therapeutics US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$125
How this compares
$2,272 in reported general payments places this provider in the 75th percentile of 3,784 obstetrics & gynecology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 19 | $9,060 |
| Estradiol | 36 | $4,998 |
| ProgesteroneProgesterone, Micronized | 18 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $219 | $9,06019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,784 obstetrics & gynecology providers in California.
Other obstetrics & gynecology in Pasadena
- Peyman BanooniBeverly Hills$9.2M
- Vellore BhupathyWhittier$4.3M
- Edwin RamirezOxnard$3.5M
- Nam TranSan Francisco$3M
- Dmitriy RomanenkoSouth Gate$2.7M
- Anita NelsonTorrance$2.1M
- Oleg BessLos Angeles$1.7M
- Rovena ReaganSan Diego$1.7M
- Dana Shippdel Mar$1.7M
- Vanessa JacobySan Francisco$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.